

April 26, 2005

#### **Establishment of Holding Company**

Mitsubishi Chemical Corporation Mitsubishi Pharma Corporation

Mitsubishi Chemical Corporation ("MCC") (Head office: Minato-ku, Tokyo; President: Ryuichi Tomizawa), and Mitsubishi Pharma Corporation ("MPC") (Head office: Chuo-ku, Osaka; President: Takeshi Komine) resolved at respective meetings of the Board of Directors held today to jointly establish a holding company ("HC"), by means of a stock-for-stock exchange effective on October 1, 2005.

#### 1. Objective

MCC has made the decision to further develop and enhance its Group portfolio management through establishing the HC, to increase the corporate value and accelerate strengthening of the pharmaceutical business, as well as expedite business restructuring and alliances. The HC will manage portfolios of the Group, with both MCC and MPC respectively managing their business operations under the HC.

MPC has also concluded that establishing the HC will accelerate its management plan to become a global research-driven pharmaceutical company, to manage domestic business environment with more stringent government control of medical costs and severer competition with overseas pharmaceutical companies. The new scheme will expand strategic options to strengthen R&D and develop overseas infrastructure through alliances, and to maximize synergies with MCC Group's health care businesses to meet changing needs in medical care.

MCC and MPC believe that the establishment of the HC will enhance our shareholders' value. The HC will also seek to increase corporate value by further executing a phased restructuring of business portfolios for other Group companies.

## 2. Process and Schedule

#### 1) Process

MCC and MPC have agreed to proceed with the establishment of the HC as follows:

Following approval at both of the companies' general meetings of shareholders

and execution of formal procedures with relevant authorities, the HC will be established in the form of a 100% parent company through the stock-for-stock exchange by MCC and MPC. MCC and MPC will both become wholly owned subsidiaries of this new entity.

At an appropriate time following the establishment, listed Group companies' shares owned by MCC will be transferred in principle to the HC, maintaining their listed status.

#### 2) Schedule

April 26, 2005 Approval by Board of Directors at MCC and MPC on

establishing the HC

April 26, 2005 Signing of the agreement on establishing the HC

Late June, 2005 General meetings of shareholders

MCC: Scheduled for June 28, 2005

MPC: Scheduled for June 29, 2005

October 1, 2005 Effective date of the stock-for-stock exchange

Listing of the HC's stock

October 3, 2005 Incorporation of the HC

#### 3. Profile of the HC

1) Company name: Mitsubishi Chemical Holdings Corporation (plan)

2) Incorporation date: October 3, 2005

3) Head office: 33-8 Shiba 5-chome, Minato-ku, Tokyo 108-0014

4) Capital: 50 billion yen

5) Listings: Tokyo Stock Exchange

Osaka Securities Exchange

6) Fiscal year end: March 31

7) Main scope of Management of Group companies

business: (Development of the Group strategies and allocation of

financial resource)

8) Directors Representative Director, Member of the Board, President:

(proposed): Ryuichi Tomizawa

Representative Director, Member of the Board:

Yosuke Yamada, Takeshi Komine

Member of the Board:

Masaoki Funada, Yoshiyuki Maekawa, Ryuichi Sato,

Hisashi Ishikawa, Kunihiko Shimojuku

Corporate Auditor (full-time):

Hideaki Yoshida, Yoshikazu Takagaki\*

Corporate Auditor:

Takayasu Kishi, Hiroyasu Sugihara\*,

Somitsu Takehara\*

\*Outside Corporate Auditor

9) Functions: 1) Portfolio management of the Group

2) Public relations and investor relations

3) Health care planning

10) Shares to be issued: 1) Type of shares: Common share

2) Number of shares: 1,806,288,107

3) Unit shares: 500

Common shares of the HC to be held by MCC via the stock-for-stock exchange will be applied toward

enhancing corporate value.

### 4. Stock-for-Stock Exchange

- 1) Stock exchange ratio
  - For each share of MCC common stock, 0.5 share of the HC's common stock
  - For each share of MPC common stock, 1.565 share of the HC's common stock

The HC will exchange its common stock with the shareholders of MCC and MPC at the ratios shown below:

	MCC	MPC
Stock exchange ratio	1	3.13

## 2) Calculation of stock-for-stock exchange ratio

The stock exchange ratio was decided through discussions by both companies based on the result of evaluation by Mitsubishi Securities Co., Ltd. in view of fairness and adequacy. MCC received fairness opinion by Nikko Citigroup Limited, and MPC received fairness opinion by Nomura Securities Co., Ltd. as their respective financial advisors.

3) Scheduled effective date of stock-for-stock exchange October 1, 2005

(Incorporation: October 3, 2005)

4) Cash payment upon the stock-for-stock exchange No cash payment will be made upon the stock-for-stock exchange. (MCC and MPC will pay interim dividends.)

## 5. Profiles of MCC and MPC


Company profiles

As of September 30, 2004

Company name	Mitsubishi Ch	emical Corporation	Mitsubishi Pharma Corporation			
Main scope of business (Consolidated)		rformance and functional and health care	Pharmaceuticals			
Establishment	Aug	ust, 1934	August, 1940			
Head office	33-8 Shiba 5-ch	ome, Minato-ku, Tokyo	6-9 Hirano-machi 2-chome, Chuo-ku, Osaka			
President	Ryuich	ni Tomizawa	Takeshi Komine			
Paid-in capital	145,08	6 million yen	30,560 million yen			
Outstanding shares	2,17	7,675,032	458,434,883			
Shareholders' equity (Consolidated)	410,69	4 million yen	199,210 million yen			
Total assets (Consolidated)	1,949,6	79 million yen	282,651 million yen			
Fiscal year end	М	March 31 March 31				
Employees (Consolidated)	;	33,603	6,085			
Major customers		s domestic and as customers	MEDICEO Holdings Co., Ltd. SUZUKEN CO., LTD.			
Major shareholders and shareholding ratios	account) – 7.68%  The Master Trust B account) – 6.40%  Meiji Yasuda Life Insu Nippon Life Insurance The Bank of Tokyo-M		Mitsubishi Chemical Corporation – 58.94%  Takeda Pharmaceutical Company Limited – 7.18%  NIPRO CORPORATION – 1.84%  The Bank of Tokyo-Mitsubishi, Ltd1.67%  The Master Trust Bank of Japan Ltd. (Trust account) – 1.49%  Japan Trustee Services Bank, Ltd. (Trust account) – 1.48%			
Main financing banks  Relationship between	The Bank of Tokyo-M THE MITSUBISHI CORPORATION Mizuho Corporate Ba Capital	TRUST AND BANKING nk, Ltd.	The Bank of Tokyo-Mitsubishi, Ltd. Sumitomo Mitsui Banking Corporation Mizuho Corporate Bank, Ltd. THE MITSUBISHI TRUST AND BANKING CORPORATION hares of MPC (58.94% of issued shares)			
MCC and MPC	Personnel	The President of MCC also serves concurrently as Chairman of MPC.				
	Business	Ordinary commercial trading				
		S. a.i.a. y Sommorbian trading				

Current three-year business results and forecasts (consolidated)								Unit: Millions of Yen	
Company name	Mitsubishi Chemical Corporation				Mitsubishi Pharma Corporation				
Fiscal year end	Actual Results (Mar. 31, 2002)	Actual Results (Mar. 31, 2003)	Actual Results (Mar. 31, 2004)	Forecasts (Mar. 31, 2005)	Actual Results (Mar. 31, 2002)	Actual Results (Mar. 31, 2003)	Actual Results (Mar. 31, 2004)	Forecasts (Mar. 31, 2005)	
Net sales	1,780,346	1,887,493	1,925,331	2,190,000	228,983	280,780	235,431	233,000	
Operating income	34,841	91,962	98,163	146,000	19,965	29,448	28,727	29,000	
Recurring profit	7,089	75,621	82,613	145,000	16,642	27,385	27,118	28,000	
Net income	-45,253	21,386	34,547	54,000	8,987	8,255	10,818	12,000	
Net income (loss) per share (Yen)	-20.78	9.75	15.82	24.84	24.54	18.05	23.81	26.50	
Cash dividends per share (Yen)	-	3	4	6	11	10	10	10	
Shareholders' equity per share (Yen)	157.86	161.06	182.59	-	420.06	416.90	435.90	-	

As of October 2005



For further information, please contact:

# Public Relations and Investor Relations Department Mitsubishi Chemical Corporation

TEL: [+81] (0)3-6414-3730

### **Forward-Looking Statements:**

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control. Actual results could differ materially due to numerous factors, including without limitation, market conditions and the effects of industry competition. The company expectations for the forward-looking statements are described in Page [1] through [6] hereof.